Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine-hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer
A series of thieno[2,3-d]pyrimidine-based hydroxamic acid hybrids was designed and synthesised as multitarget anti-cancer agents, through incorporating the pharmacophore of EGFR, VEGFR2 into the inhibitory functionality of HDAC6. Three compounds (12c, 15b and 20b) were promising hits, whereas (12c)...
Saved in:
Main Authors: | Mona M. Abdel-Atty (Author), Nahla A. Farag (Author), Rabah A. T. Serya (Author), Khaled A. M. Abouzid (Author), Samar Mowafy (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Furo[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents
by: Marwa A. Aziz, et al.
Published: (2016) -
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma
by: Shaymaa E. Kassab, et al.
Published: (2019) -
In silco studies on modified hydroxamic acid and valporic acid as potential inhibitors for HDAC2
by: Naresh Kandakatla, et al.
Published: (2013) -
In silico studies on modified hydroxamic acid and valporic acid as potential inhibitors for HDAC2
by: Naresh Kandakatla, et al.
Published: (2013) -
Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents
by: Eman Z. Elrazaz, et al.
Published: (2015)